Related Experiment Video
Updated: Jun 8, 2026
15:53
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
Do we have to kill the last CML cell?
D M Ross1, T P Hughes, J V Melo
1Department of Haematology, SA Pathology Centre for Cancer Biology, University of Adelaide, Adelaide, Australia.
Leukemia
|September 17, 2010
Summary
Achieving deep molecular remission in chronic myeloid leukemia (CML) does not guarantee eradication. Further research is needed to understand relapse risks after stopping imatinib treatment in patients with CML.
Area of Science:
- Hematology
- Molecular Biology
- Cancer Research
Background:
- Chronic myeloid leukemia (CML) treatment aims for deeper responses beyond clinical remission.
- Complete molecular response (CMR), defined by undetectable BCR-ABL mRNA, is a significant milestone.
- However, CMR's significance depends on assay sensitivity, and eradication is not guaranteed.
Purpose of the Study:
- To discuss sensitive measurement of minimal residual disease in CML.
- To explore the biology of persistent BCR-ABL-positive cells after effective CML therapy.
- To review ongoing studies on imatinib cessation in patients with CMR.
Main Methods:
- Analysis of data from ongoing imatinib cessation studies in CML patients with CMR.
- Discussion of sensitive minimal residual disease (MRD) detection techniques.
- Speculation on the biological factors influencing CML relapse after treatment withdrawal.
Main Results:
- Approximately 40% of CML patients maintain stable CMR after imatinib cessation, based on current short-term follow-up.
- Factors determining relapse risk after imatinib cessation remain unidentified.
- No current test can definitively prove eradication of the CML clone.
Conclusions:
- Deeper molecular monitoring is crucial for assessing CML treatment efficacy.
- Understanding residual CML cell biology and immune system interactions is key to preventing relapse.
- Further long-term studies are essential to identify relapse predictors and optimize CML management strategies.
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:28The Cell Cycle Control System
The cell cycle regulation directs how a cell proceeds from one phase to the next and begins mitosis. The cell cycle control system includes intracellular regulatory molecules and external triggers. They provide "stop" or "advance" signals and operate at specific cell cycle stages termed checkpoints to ensure that a particular process is completed before the cell advances to the next phase.
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:21Lineage Commitment
Commitment is the process whereby stem cells:
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...